Recent Posts
Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual MeetingNovember 12, 2021
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumorsJune 24, 2021
Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumorsMarch 25, 2021